A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration

Trial Profile

A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Adult neural stem cells (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Proof of concept; Therapeutic Use
  • Acronyms RADIANT
  • Sponsors StemCells
  • Most Recent Events

    • 31 May 2016 Status changed from suspended to discontinued based on a business decision unrelated to any safety concerns.
    • 23 Dec 2015 According to a StemCells media release, the company has decided to suspend this trial in line with a strategic realignment to fully focus the company's resources on its proprietary HuCNS-SC platform technology for the treatment of chronic spinal cord injury (SCI). The company is seeking a partner to fund continued development in retinal disorders.
    • 23 Dec 2015 Status changed from recruiting to suspended, according to a StemCells Inc., media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top